ASH 2020 | Promising early results of a novel anti-CD123 antibody-drug conjugate in R/R BPDCN
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings of a trial (NCT03386513) of IMGN632, a novel antibody-drug conjugate (ADC), for use in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), a setting with poor outcomes and minimal treatment options. As CD123 overexpression is characteristic of BPDCN, the ADC is composed of an anti-CD123 antibody and a DNA-alkylating indolinobenzodiazepine dimer (IGN). Given the limited efficacy and tolerability concerns of current treatment options for these patients, the responses to IMGN632 and the favorable safety profile observed are promising, especially since half the cohort had prior anti-CD123 exposure. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Naveen Pemmaraju, MD, has received research funding or grant support from Samus Therapeutics, Cellectis, Stemline Therapeutics, AbbVie, Plexxikon, LFB Biotechnologies, Novartis, SagerStrong Foundation, Affymetrix and Daiichi Sankyo; has received honoraria from Roche Diagnostics, Celgene, Stemline Therapeutics, DAVA Oncology, AbbVie, Incyte Corporation, Blueprint Medicines, Novaritis and MustangBio; and has done consultancy work for Pacylex Pharmaceuticals.
